Program Snapshot

The goal of the Illuminating the Druggable Genome (IDG) Program is to improve our understanding of the properties and functions of proteins that are currently not well studied within commonly drug-targeted protein families. IDG began in 2014 and received funding for a three year pilot phase. The pilot phase of the program developed a website, called Pharos, that integrates information about understudied proteins so that researchers everywhere can easily access it, catalyzing their own research and helping them find new proteins that may be of interest. In addition, IDG supported researchers developed technologies to enable the study of understudied druggable proteins in a high throughput manner. During 2017, IDG was approved for a second stage of funding, called the Implementation Phase. During the Implementation Phase, IDG aims to expand the informatics tools developed in the Pilot Phase, elucidate the function of understudied proteins from three key druggable protein familes (GPCRs, ion channels, and kinases), and disseminate the IDG-generated resources to the greater scientific community.

Learn More at the IDG Consortium Website

IDG Consortium logo

The goal of the Illuminating the Druggable Genome (IDG) program is to improve our understanding of the properties and functions of proteins that are currently unannotated within the four most commonly drug-targeted protein families: the G-protein coupled receptors, ion channels, and protein kinases.  Learn more about the IDG Consortium by visiting the website

This page last reviewed on April 30, 2018